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Abstract
Background: Short interfering RNAs have allowed the development of clean and easily regulated
methods for disruption of gene expression. However, while these methods continue to grow in
popularity, designing effective siRNA experiments can be challenging. The various existing siRNA
design guidelines suffer from two problems: they differ considerably from each other, and they
produce high levels of false-positive predictions when tested on data of independent origins.
Results: Using a distinctly large set of siRNA efficacy data assembled from a vast diversity of origins
(the siRecords data, containing records of 3,277 siRNA experiments targeting 1,518 genes, derived
from 1,417 independent studies), we conducted extensive analyses of all known features that have
been implicated in increasing RNAi effectiveness. A number of features having positive impacts on
siRNA efficacy were identified. By performing quantitative analyses on cooperative effects among
these features, then applying a disjunctive rule merging (DRM) algorithm, we developed a bundle of
siRNA design rule sets with the false positive problem well curbed. A comparison with 15 online
siRNA design tools indicated that some of the rule sets we developed surpassed all of these design
tools commonly used in siRNA design practice in positive predictive values (PPVs).
Conclusion:  The availability of the large and diverse siRNA dataset from siRecords  and the
approach we describe in this report have allowed the development of highly effective and generally
applicable siRNA design rule sets. Together with ever improving RNAi lab techniques, these design
rule sets are expected to make siRNAs a more useful tool for molecular genetics, functional
genomics, and drug discovery studies.
Background
Short interfering RNAs (siRNAs) are double-stranded
RNAs typically of length between 19 and 25 with 2
nucleotide overhangs on the 3' ends, and they are capable
of inducing sequence-specific, post-transcriptional dele-
tion of gene products, leading to the silencing of the gene
activity. Naturally occurring siRNAs are cleavage products
from long double-stranded RNAs (dsRNAs) by Dicer, a
ribonuclease III enzyme [1,2]. The siRNA-induced mRNA
degradation is a complicated process involving multiple
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steps, initiated by the binding of siRNA with RISC (RNA
induced silencing complex), followed by RISC's activa-
tion, resulting in the recognition of the target mRNA and
the degradation of the latter [1,3,4]. As a gene knock-
down tool used in labs, siRNAs can also be chemically
synthesized and introduced into the cells by direct trans-
fection [5,6] or delivered into the cells in forms of hairpin
precursors through plasmid or viral vectors [7,8]. The
siRNA-based gene knock-down techniques are preferred
by many because of their ability to disrupt individual
gene's function without affecting related genes [9]. These
techniques are particularly attractive for gene silencing
studies in mammalian cells, because, unlike longer dou-
ble-stranded RNAs, siRNAs are not likely to trigger inter-
feron responses which lead to non-specific mRNA
degradation [5].
The efficacy issue represents a major challenge in siRNA
design. This issue concerns the question of how to choose
from the large number of candidate siRNAs the ones that
give rise of the highest levels of knock-down activity. It is
well known that only a fraction of these candidate siRNAs
are highly effective in silencing the target genes. Two siR-
NAs targeting the mRNA sites that are separated by only a
few nucleotides could exhibit very different knock-down
efficacies [10,11]. What are the properties some siRNAs
possess that render them more effective in knocking down
the target genes than others? This is an issue of heated
debate. Several sets of rules for designing high-efficacy siR-
NAs have been proposed (e.g., [11-14]). In addition, a
long list of factors have been claimed to influence siRNA
knock-down efficacy and thus should be considered in
siRNA design [15-26].
There are significant disagreements among these design
rules and considerable controversies over these claims.
This situation has been discussed extensively in several
recent review articles [27,28], therefore we only list some
examples of these disagreements here: [20] suggested that
the sequence information alone was sufficient in deter-
mining the efficacy of a siRNA; however, [15,22,24] advo-
cated the need to incorporate thermodynamic properties
(calculated using tools such as Mfold [29]) in assisting
siRNA design; while [17,25] emphasized the importance
of the accessibility to the mRNA sites by the siRNAs, and
endorsed methods of filtering candidate siRNAs based on
mRNA secondary structure properties. On factors deter-
mined by siRNA sequences, [12,30] recommended choos-
ing of sequences of intermediate G/C contents (around
50%) for effective siRNAs, while [11,18,24,31,32]
endorsed the choosing of sequences of lower G/C con-
tents (< 60%) to increase the chance of making high-effi-
cacy siRNAs. On position-specific properties, [11]
suggested that the nucleotides on positions 3, 10, 13 and
19 on the sense strand played a critical role in determining
the knock-down efficacy; while [14] claimed that posi-
tions 19 and 11, and perhaps 6, 13 and 16 on the sense
strand were important in determining the knock-down
efficacy of the siRNAs.
The debates over siRNA efficacy go beyond the disagree-
ments among these design rules. In fact, the effectiveness
of these rules per se is in question. [17] showed that most
published siRNA design tools output large numbers of
ineffective siRNAs, and had a similar performance to (or
even worse than) a random selector when tested on data
of an independent origin. [20] made similar observations,
and alleged that several published efficacy predicting algo-
rithms gave close to random classification on unseen data.
At least two groups of researchers pointed out that many
existing studies on siRNA design criteria suffered from the
"overfitting" problem [20,24]. This term describes scenar-
ios where rules are extracted from datasets that have small
sample sizes, low signal-to-noise ratios, and unique exper-
imental settings. Rules obtained under these conditions
are prone to spurious effects caused by noise in the data
samples or specific aspects of the experimental settings or
both; rules obtained in this manner are likely to perform
unsatisfactorily when used on data obtained under differ-
ent experimental settings.
The key to countering the overfitting problem and devel-
oping truly effective and generally applicable siRNA
design rules is the availability of a large collection of
siRNA efficacy data from diverse origins. We recently
undertook the effort to document all siRNA experiments
in published studies and provide sensible efficacy ratings
of these experiments. This effort resulted in siRecords, the
largest known curated database of mammalian siRNA
experiments with consistent efficacy ratings [33]. The
availability of the siRecords data makes it possible to better
analyze factors responsible for achieving effective RNAi
experiments.
In this study, we first conducted a survey on the siRecords
data of all known "features" previously implicated to
influence siRNA knock-down efficacy. This survey
resulted in a list of features that significantly boosted the
chance of achieving higher siRNA efficacies. Then, we
examined quantitatively how these significant features
interact with one another in their joint effects on achiev-
ing higher efficacies. The combinations of features that
give rise to the highest levels of boosting to siRNA effica-
cies were picked and reorganized using a disjunctive rule
merging (DRM) procedure, which led to a bundle of non-
redundant rule sets with controlled stringency level. The
performance of these rule sets (termed the DRM rule sets)
was then assessed using a reserved dataset and comparedBMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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with existing design tools commonly used in current
siRNA design practice.
An implementation of the DRM rule sets developed in this
study is available for testing as an online siRNA design
server [34].
Results
Overview of siRecords data
siRecords  is a continuing effort aimed to document all
mammalian siRNA experiments reported in literature,
and provide systematically rated efficacies for these exper-
iments [33]. Currently, about 9000 records of siRNA
experiments targeting more than 3000 genes are hosted in
the siRecords  database. For each siRNA experiment, we
document the siRNA sequence, the target gene, key infor-
mation about experimental conditions (cell line used; the
method of producing the siRNA – chemically synthesized
or vector-based; the method of testing the siRNA efficacy
– western blot or real-time PCR or others), and an efficacy
rating (elaborated below).
For this investigation, we picked all complete records of
19-mer siRNA experiments (21-mers if the two overhang-
ing nucleotides on the 3' ends are counted) from the
siRecords collection (dated 12/12/2005). The distribution
of number of records per study is highly skewed – about
17.5% of the records (657 siRNA experiments) originated
from 0.4% of the studies (6 studies, each reporting ≥ 30
siRNA experiments, Figure 1). To prevent our analyses
from being biased by this small number of studies, we
limited the number of siRNA experiments originated from
a single study to be ≤ 30. For these studies where more
than 30 siRNA experiments were reported, we randomly
picked 30 to include in our analyses and discarded the
rest. The resulting dataset includes the records of 3277
siRNA experiments targeting 1518 genes originated from
1417 independent studies. We randomly divided the
dataset into two subsets at a 2:1 ratio. The larger subset –
termed Set A – included 2184 records, and was used to
survey features significantly associated with high efficacies
and analyze the combinatorial effects of these features.
The other subset (termed Set T, 1093 records) was
reserved to test the conclusions obtained through the
analyses of Set A.
Survey of features significantly boosting siRNA efficacy
We set out to determine, using the Set A data, what "fea-
tures" of the siRNA experiments are associated with ele-
vated RNAi efficacies. A feature is a binary property of a
siRNA experiment concerning a factor potentially relevant
to siRNA efficacy, for example, the 6th nucleotide of the
siRNA sequence = A. Each feature has a "complementary
feature". A feature and its complementary feature consti-
tute a "feature pair". More discussions about the defini-
tion of feature and related terms can be found in Methods.
In siRecords, the effectiveness of any siRNA experiment is
rated on a four-level scale: very high (if the gene product
was reduced by ≥ 90%), high (if the gene product was
The distribution of the number of siRNA experiments per study is highly skewed in the siRecords collection Figure 1
The distribution of the number of siRNA experiments per study is highly skewed in the siRecords collection. A. Studies were 
categorized based on the number of siRNA experiments reported. Only 6 out of the 1,417 studies (0.4%) reported > 30 
siRNA experiments per study. B. The distribution of the total number of records in each category. Six hundred and fifty-seven 
records (representing 17.5% of the entire dataset) originated from the 6 studies with > 30 records per study.BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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reduced by 70–90%), medium (if 50–70% knock-down
was achieved); and low (if < 50% knock-down was
observed). In Set A, the percentages of records receiving
very high, high, medium and low efficacy ratings are
34.1%, 34.6%, 16.3% and 14.9% respectively (Figure 2).
The decision of using this four-level rating scheme was
made based on balanced considerations about the useful-
ness and the reliability of the ratings [33]. One conse-
quence of this decision is that that the conventional t-test
type of analysis [11] can not be performed on this dataset,
because the dependent variable (efficacy rating) is not a
continuous variable, but rather a categorical, ordinal vari-
able. Proper categorical analysis techniques need to be
adopted to analyze this type of data [35].
We chose to use the Wald test of monotone trend to assess
the evidence that the presence of a feature is associated
with a significant up-shift (or down-shift) of the efficacy
distribution. In addition, we conducted odds ratio permu-
tation tests for two efficacy levels: > 90% and > 70% effi-
cacies, because in siRNA design practice, we are interested
in assessing whether a feature leads to increased chances
of achieving higher efficacies (see Methods). For instance,
a Wald test of monotone trend indicated that the presence
of the feature the 6th nucleotide of the siRNA sequence = A is
associated with significant up-shift of the efficacy distribu-
tion (P = 0.0058); odds ratio permutation tests showed
that the presence of this feature led to significant increase
in the probabilities of achieving both > 90% (P = 0.043)
and > 70% (P = 0.0024) efficacies (see Supplementary Fig-
ure 1 in Additional file 1).
We examined 276 features (they constitute 138 "feature
pairs") for their association with higher RNAi efficacies,
using the Wald test of monotone trend and the odds ratio
permutation tests. The features we examined include, to
our knowledge, all that have been implicated in previous
studies to improve siRNA effectiveness. Each of these fea-
tures can be placed into one of five categories. The first cat-
egory is based on nucleotide identities at specific
positions on the 19-mer siRNA sequence, e.g. the 6th
nucleotide = A; there are 76 feature pairs in this category.
The second category includes 19 feature pairs that are
either composite sequence features, e.g. there are at least
three (A/U)'s in the seven nucleotides at the 3' end of the
siRNA, or features that are defined based on the G/C con-
tent of the siRNA. The third category consists of 13 feature
pairs that are based on the thermodynamics of the siRNAs
Survey of features associated with the achievement of higher efficacies Figure 2
Survey of features associated with the achievement of higher efficacies. The efficacy of a siRNA experiment is rated on a four-
level scale. In Set A, the percentages of records achieving these ratings are 34.1%, 34.6%, 16.3% and 14.9%, respectively. The 
distribution of the efficacy ratings across the four levels changes when certain feature is present in the siRNA experiments. For 
14 selected features (they constitute 7 pairs of "complementary features"), the efficacy rating distributions of the subpopula-
tions of siRNA experiments carrying these features are presented. Dotted vertical lines extend from the distribution of the 
general population.BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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as measured by the melting temperature, or binding
energy. The fourth category, consisting of 16 feature pairs,
includes features based on target mRNA sites, such as the
relative positions of the target sites on the mRNA, and the
local secondary structures of the target regions. Finally,
the fifth category includes 14 feature pairs that are based
on experimental settings, such as the cell lines used in the
experiments (HeLa cells, HEK293 cells, and others), the
methods used for making and delivering the siRNAs, and
the methods used to evaluate the efficacy of the siRNA
(Western blot, PCR-based, and others). The complete list
of these tested features, and references to the studies that
implicated them in enhancing siRNA efficacies, are pro-
vided in Supplementary Tables 1-5 in Additional file 1.
Of the features examined, we found 34 that were associ-
ated with a significant improvement in the efficacy distri-
bution (P < 0.01, Wald test of monotone trend; FDR
controlled at 0.056 by the q-value technique [36]); among
which, 26 significantly elevated the chance of achieving >
90% efficacies (P < 0.01, odds ratio permutation test, FDR
controlled at 0.038), and 27 significantly enhanced the
probability of achieving > 70% efficacies (P < 0.01, odds
ratio permutation tests, FDR controlled at 0.044; see Sup-
plementary Tables 1-5  in Additional file 1). There are sev-
eral cases of sub-feature – super-feature relationships
among these significant features. For example, the features
the 6th nucleotide = A, and the 6th nucleotide ≠ C were
both significant features, however, the former is a sub-fea-
ture of the latter since when the former feature is present,
the latter must also be present. In each occurrence of sub-
feature – super-feature relationship, we eliminated all but
the one feature determined to be the most significant by
the Wald test. The feature the 6th nucleotide = A was thus
eliminated because the Wald test P value of this feature
was higher than that of the feature the 6th nucleotide ≠ C.
G/C content related features were treated as a special case.
Several different G/C content ranges were suggested in
previous studies as being possibly associated with high
RNAi effectiveness (32–79%, 30–70%, 30–52%, 35–
60%, 20–50% and 31.6–57.9%) [11,12,18,24,30-32]. All
these features were tested. Although they do not constitute
sub-feature – super-feature relationships, we treated these
features as redundant features, and retained only one of
them (G/C content is between 35 and 60%) because it
yielded the lowest P value (0.00018) in the Wald test. The
resulting list of non-redundant significant features is
shown in Table 1. Detailed discussions about these signif-
icant features, and comparisons of our analyses with pre-
vious findings can be found in the Additional file 1.
Combined effects of multiple significant features
The presence of any single significant feature was not suf-
ficient to improve the efficacy distribution substantially.
When present alone, the significant features listed in Table
1 increased the probability of achieving > 90% efficacies
by an average of only 2.5% (from 34.1% to 36.6%), and
they increased the chance of achieving > 70% efficacies by
Table 1: Non-redundant significant features meeting the criteria (Pwald < 0.01) and (P70 < 0.01 or P90 < 0.01)
Feature name % Low % Medium % High % Very high P70 P90 Pwald
2nd nucleotide = A 12.1 16.0 33.8 38.1 0.01 0.0026 0.0019
4th nucleotide = C 14.1 15.4 31.5 39.0 0.098 0.00036 0.0075
6th nucleotide ≠ C 14.3 15.6 35.0 35.1 0.00066 0.0089 0.0052
7th nucleotide ≠ U 14.4 15.9 34.5 35.2 0.01 0.0043 0.0091
9th nucleotide = C 11.1 16.6 32.6 39.6 0.008 0.00021 0.00053
17th nucleotide = A 11.4 15.5 37.1 35.9 0.00049 0.1 0.0049
18th nucleotide ≠ C 14.4 15.9 34.3 35.4 0.01 0.00071 0.0048
19th nucleotide = (A/U) 12.0 16.0 35.3 36.7 0.00029 0.0043 0.000058
At least three (A/U)s in the seven nucleotides at the 3' end 13.4 16.4 33.7 36.5 0.00001 0.00001 2.5E-09
No occurrences of four or more identical nucleotides in a row 14.2 15.9 35.4 34.5 0.00001 0.012 0.0014
No occurrences of G/C stretches of length 7 or longer 14.3 16.4 34.9 34.4 0.00001 0.00001 0.000015
G/C content is between 35% and 60% 13.3 16.7 35.1 35.0 0.00001 0.0019 0.00018
Tm is between 20 and 60°C 13.2 16.5 35.0 35.3 0.0045 0.023 0.003
Binding energy of N16–N19 > -9 KCal/Mol 11.8 17.1 34.0 37.1 0.01 0.0026 0.00025
Binding energy of N16–N19 – binding energy of N1–N4 is 
between 0 and 1 KCal/Mol
12.6 14.9 32.5 39.9 0.01 0.00036 0.0078
Local folding potential (mean) ≥ -22.72 KCal/Mol 12.0 14.6 34.7 38.7 0.00001 0.00001 9.3E-09
Target site is on CDS 14.4 16.2 34.3 35.2 0.00001 0.00001 0.000055
Cell line = HeLa 7.9 10.6 41.2 40.3 0.00001 0.00016 4.0E-09
Test method = Western blot 10.8 15.5 34.8 36.9 0.00001 0.00001 3.8E-14
Test object ≠ mRNA 13.1 14.5 34.8 37.6 0.00001 0.00001 9.3E-10
At P < 0.01, the FDR for the three tests: Wald test of monotone trend, permutation test of odds ratios (> 70%) and permutation test of odds ratios 
(> 90%) were controlled at the levels of 0.056, 0.044 and 0.038 respectively.BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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an average of merely 2.2% (from 68.7% to 70.9%). To
achieve substantially improved efficacies, the concurrent
presence of several significant features is required.
When multiple features are co-present, we cannot assume
that their contributions to the effectiveness of the RNAi
experiments are additive, since features are not always
independent of one another. For instance, the presence of
the feature the 19th nucleotide = (A/U), clearly increases the
probability that the feature there are at least three (A/U)'s in
the seven nucleotides on the 3' end of the siRNA to be true.
Indeed, these two features exhibited negative cooperativ-
ity: when present alone, they increased the chances of
achieving > 90% efficacies by 2.6% and 2.4%, respec-
tively; when co-present, these two features resulted in
merely a 2.7% increase in the chance of achieving > 90%
efficacy, much smaller than the sum of the effects of the
two features (see Additional file 1 for discussions about
cooperativity and additive effects of multiple features).
In seeking effective siRNA design rules, we should try to
identify combinations of features that exhibit positive
cooperativity. The large size and diverse origins of the
records in the siRecords dataset allowed us to systemati-
cally analyze how features jointly influence siRNA effica-
cies. Three significant features: Cell line = HeLa, Test method
= Western blot and Test object ≠ mRNA were excluded from
joint effect analyses because they are based on experimen-
tal settings, which are typically chosen independent of
siRNA design. For the remaining 17 significant features,
we looked at all possible combinations of a fixed number
(l = 2,3,4,5 and 6) of features. For each combination of l
features, we examined the number of records in Set A that
concurrently carry all l features, and the percentages of
these records that achieved > 90% and > 70% efficacies.
For every given l, we focused on the top-10 feature combi-
nations, i.e., the 10 combinations that exhibited the high-
est percentage of records achieving > 90% or > 70%
efficacies. When there was a tie of more than 10 feature
combinations, all tied combinations were considered. As
we expected, as l – the number of features in the combina-
tions increased, the number of records concurrently carry-
ing all l features declined sharply (Figure 3C). Meanwhile,
the percentage of experiments achieving > 90% and >
70% efficacies increased steadily as l, the number of fea-
tures included in the feature combinations, increased
(Figure 3A and 3B).
Highly effective siRNA design rules were obtained by selecting the top l-feature combinations, i.e., the combination of l non- redundant significant features that exhibited the highest percentages of records achieving > 70% or > 90% efficacies on Set A Figure 3
Highly effective siRNA design rules were obtained by selecting the top l-feature combinations, i.e., the combination of l non-
redundant significant features that exhibited the highest percentages of records achieving > 70% or > 90% efficacies on Set A. 
A. For l = 2 through 6, the subpopulations of Set A records that carry all combinations of l features were examined, and the 10 
feature combinations (FCs) that resulted in the highest percentages of records achieving > 70% efficacies were selected. When 
there was a tie of more than 10 FCs, all of them were considered (marked in the graph). The mean percentages of the top FCs 
are presented in black filled circles. These FCs were used to select siRNA experiments in the Set T, and the results are shown 
in grey filled circles. Error bars indicate standard errors. The first two data points in the graphs represent the base line levels 
(the percentage of records achieving > 70% efficacies for the entire Set A or Set T), and the mean levels for top-10 individual 
features (the 10 individual features that led to highest percentages of records achieving > 70% efficacies), respectively. B. Simi-
larly to A, the top FCs selected with > 90% efficacies are plotted, together with the baseline levels and the mean levels for top 
individual features. C. The numbers of records selected in the top l-feature combinations dropped sharply as l increased. The 
mean numbers of selected records for Set A (with error bars indicating standard errors) are presented in black filled circles 
and black open circles for > 70% and > 90% efficacies, respectively. The numbers of selected records for Set T are presented 
in corresponding grey symbols. Again, the first two data points represent the baseline levels (numbers of records in entire Set 
A and Set T), and the numbers of records selected with the top-10 individual features, respectively.
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The sigmoid shape of the two ascending curves is an indi-
cation of positive cooperativity (see discussion in Addi-
tional file 1). This suggests that by simply retaining the
feature combinations that led to the highest percentages
of records achieving efficacies of > 90% or > 70%, we
were, in effect, exploiting the positive cooperativity, or
favorable interaction, among these features. At l = 5, 24
feature combinations had a 100% chance of having effica-
cies > 70%, that is, every experiment in which the siRNA
used had all features contained in any one of the 24 fea-
ture combinations exhibited efficacies of > 70%. Simi-
larly, 14 feature combinations had 100% probabilities of
having efficacies > 90% at l = 5, meaning that all siRNA
experiments having these feature combinations demon-
strated efficacies > 90%. At l = 6, 188 feature combinations
had 100% probabilities of having efficacies of > 70%, and
94 feature combinations had 100% probabilities of
achieving efficacies of > 90%.
Integrated rule sets for effective siRNA design
A disjunction of the top feature combinations described
above (across l = 2 through 6; a feature combination is
also called a rule thereafter) defines a rule set for designing
effective siRNA experiments. Rule sets defined in this way
are likely to contain redundancies, because if a rule con-
sisting of   features {f1, f2,...,  } is one of the best   -fea-
ture combinations, then a rule consisting of ( +1)
features {f1, f2,..., ,  f0}, where f0 is any other feature, is
likely to be one of the best ( +1)-feature combinations
thus is also selected into the rule set. A disjunctive rule
merging  (DRM) algorithm can be applied to remove
redundancies of the rule sets, in the mean time allowing
the control over the stringency of the resulting rule sets
(see Methods). This algorithm takes in a user-provided
stringency parameter α (which has a range of [0, 1]), and
produces a non-redundant set of disjunctive rules, each
rule in the set resulting in ≥ α proportion of the records in
Set A reaching efficacies > 90%. The rule set rendered for
the highest α level (α = 0.951, denoted as RS0.951) con-
tains seven rules (Table 2). Generally speaking, the lower
α level, the larger number of rules are included in the rule
set (see Supplementary Table 6 in Additional file 1).
Performance comparison between DRM rule sets and 
existing design tools
We assessed the performance of the DRM rule sets, and
compared it with that of 15 existing online design tools
commonly used in siRNA design practice, using the Set T
data reserved for this purpose (Table 3 and Figure 4). Set
T includes the records of 1,093 siRNA experiments, repre-
senting 1,014 unique target sites on 744 genes. How do
we assess the performance of a siRNA design program? A
good siRNA design program should (a) provide a suffi-
cient number of candidate siRNAs for a given gene; and
(b) offer a high PPV (positive predictive value), or a low
false positive rate (see Methods).
On the number of candidate siRNAs predicted, the DRM
rule set with the highest stringency level (RS0.951) pro-
duced on average 18.9 predicted effective siRNAs per
gene. This indicates that this rule set offers sufficient can-
didate siRNAs in an ordinary siRNA design task for a gene
of an average length. However, the smallest number of
predicted effective siRNAs for a gene is 1. This suggests
that for genes of the shortest lengths, the number of can-
didate siRNAs offered by this rule set may not be enough.
There are considerations other than achieving high effi-
cacy (e.g., avoiding cross-reactivity with other genes) in
the design of siRNA experiments, thus it is desirable to
have multiple candidate siRNAs designed for every gene.
For genes of the shortest lengths, we resort to DRM rule
sets of lower stringency levels. For example, RS0.845 pro-
duced at least 3 potentially effective siRNAs for each gene,
and an average of 38.1 potentially effective siRNAs per
gene (see Supplementary Figure 3 in Additional file 1).
The online design tools varied greatly in the numbers of
candidate siRNAs they provided. The highest number of
predicted effective siRNAs was offered by EMBOSS sirna
by Institute Pasteur (639.4 siRNAs per gene). IDT RNAi
Design by IDT, Inc. produced the lowest number of pre-
dicted effective siRNAs (5.8 siRNAs per gene). Among the
15 online design tools, 10 offered larger numbers of can-
didate siRNAs than DRM RS0.951, and 4 provided larger
numbers of candidate siRNAs than DRM RS0.845.
Given that a sufficient number of candidate siRNAs are
provided, the most important parameter that measures
the performance of a design tool is the PPV. Only a small
proportion of possible siRNA sites have been experimen-
tally tested for effectiveness (1,014 sites among 2,453,510
possible 19-mer sites on the 744 genes). Based on these
experimentally tested siRNA sites, we compared the PPVs
of the DRM rule sets to those of 15 existing online design
tools. For the "> 90% efficacy" setting and "> 70% effi-
cacy" setting, DRM RS0.951 showed PPVs of 72.7% and
90.9%, respectively. In other words, 72.7% of the pre-
dicted effective siRNAs by DRM RS0.951 had > 90% effi-
cacy, and 90.9% of the predicted effective siRNAs showed
> 70% efficacy. This rule set and two others with lower α
level, RS0.895 and RS0.845 surpassed all online design tools
in PPVs on both settings. Among the 15 online design
tools, the three that offered the highest PPVs for the ">
90% efficacy" setting were WI siRNA Selection Program by
Whitehead Institute (53.8%), siDESIGN Center by Dhar-
macon Inc. (48.5%) and BLOCK-iT RNAi Designer by Inv-
ˆ l fl ˆ ˆ l
ˆ l
fl ˆ
ˆ lBMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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itrogen Corp. (47.6%), respectively; and the four that
offered the highest PPVs for the "> 70% efficacy" setting
were siRNA Target Finder by GenScript Corp. (85.2%), WI
siRNA Selection Program by Whitehead Institute (84.6%),
siDESIGN Center by Dharmacon. Inc. (81.8%) and siRNA
Target Designer by Promega Corp. (81.8%), respectively.
Set T is a fair dataset to be used for the purpose of perform-
ance comparison between the DRM rule sets and the
online design tools, because it contains no overlapping
records with Set A, based on which the DRM rule sets were
derived. However, Set T might not be considered as a com-
pletely independent dataset, because (a), there are records
in Set T that originated from the same studies as some
records in Set A; and (b), there are records of siRNA exper-
iments in Set T that target the same genes as some experi-
ments in Set A. To rule out the possibility that these two
factors might contribute to better performance of the
DRM rule sets for unforeseen reasons and unfairly favor
the DRM rule sets in the performance comparison, we
compiled an "independent subset" of Set T, eliminating
all records that share the same origins of any records in Set
A, and all records that target the same genes that are also
targeted by any records in Set A. We compared the per-
formance of the DRM rule sets with that of the 15 online
design tools using this independent subset (including 224
siRNAs targeting 197 different genes, see Table 4). Because
of the reduced size of the dataset (by nearly 80%), the sen-
sitivity, specificity and PPVs for all tools and rule sets
showed higher levels of variability. The three DRM rule
sets with the highest α levels: RS0.951, RS0.895 and RS0.845
achieved 100% PPV. Two online design tools, BLOCK-iT
by Invitrogen Corp. and WI siRNA Selection Program by
Whitehead Institute also achieved 100% PPV, but the
other online design tools achieved lower PPVs that range
between 50.0% and 86.4%. Although the small size of the
independent subset prevented this analysis from being
completely conclusive, it is fair to state that the compari-
son made based on the independent subset is generally in
agreement with the comparison made based on the entire
Set T.
Discussion
It has been recognized that many existing siRNA design
criteria (and the design tools in which they are imple-
mented) failed to provide promised levels of performance
Table 2: Non-redundant DRM rule set for the highest α level:RS0.951.
Feature F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17
Rule 1 √√ √ √
Rule 2 √√√ √ √
Rule 3 √√ √ √ √ √
Rule 4 √√ √ √ √ √
Rule 5 √ √ √√√√
Rule 6 √ √√√√ √
Rule 7 √√ √ √ √ √
List of features:
Feature 
Index
Feature Names
F1 2nd nucleotide = A
F2 4th nucleotide = C
F3 6th nucleotide ≠ C
F4 7th nucleotide ≠ U
F5 9th nucleotide = C
F6 17th nucleotide = A
F7 18th nucleotide ≠ C
F8 19th nucleotide = (A/U)
F9 At least three (A/U)s in the seven nucleotides at the 3' end
F10 No occurrences of four or more identical nucleotides in a row
F11 No occurrences of G/C stretches of length 7 or longer
F12 G/C content is between 35 and 60%
F13 Tm is between 20 and 60°C
F14 Binding energy of N16–N19 > -9 KCal/Mol
F15 Binding energy of N16–N19 – binding energy of N1–N4 is between 0 and 1 KCal/Mol
F16 Local folding potential (mean) ≥ -22.72 KCal/Mol
F17 Target site is on CDSB
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Table 3: Comparison in performance between 15 online siRNA design tools and DRM rule sets with four different stringency levels (α = 0.951, 0.895, 0.845 and 0.827).
Design Program Institution/Company URL Avg. # 
Effective 
siRNAs
Predicted 
per Gene
Sensitivity
(> 90%)
Specificity
(> 90%)
PPV
(> 90%)
Sensitivity
(> 70%)
Specificity
(> 70%)
PPV (> 
70%)
Ambion siRNA Target Finder Ambion, Inc. [64] 190.0 0.603 0.456 37.0% 0.574 0.457 70.3%
Jack Lin's siRNA Sequence Finder Cold Spring Harbor Laboratory [65] 207.5 0.204 0.759 30.9% 0.221 0.757 67.1%
siDESIGN Center Dharmacon, Inc. [66] 9.8 0.042 0.976 48.5% 0.036 0.982 81.8%
siRNA Target Finder GenScript Corp. [67] 22.4 0.032 0.979 44.4% 0.030 0.988 85.2%
Imgenex sirna Designer Imgenex Corp. [68] 22.8 0.116 0.913 41.5% 0.108 0.929 77.4%
EMBOSS sirna Institute Pasteur [69] 639.4 0.778 0.250 35.4% 0.767 0.258 69.9%
IDT RNAi Design (SciTools) Integrated DNA Technologies, Inc. [70] 5.8 0.032 0.975 40.0% 0.030 0.979 76.7%
BLOCK-iT RNAi Designer Invitrogen Corp. [71] 11.4 0.026 0.985 47.6% 0.020 0.982 71.4%
siSearch Karolinska Institutet [72] 19.6 0.016 0.986 37.5% 0.017 0.991 81.3%
SiMAX MWG-Biotech, Inc. [73] 35.1 0.161 0.843 35.3% 0.172 0.872 75.1%
BIOPREDsi Novartis Institutes for BioMedical 
Research
[74] 10.0 0.794 0.908 31.3% 0.820 0.899 64.6%
Promega siRNA Target Designer Promega Corp. [75] 38.0 0.093 0.941 45.5% 0.083 0.958 81.8%
QIAGEN siRNA Design Tool QIAGEN, Inc. [76] 29.6 0.167 0.862 38.9% 0.161 0.881 75.3%
SDS/MPI University of Hong Kong [77] 432.8 0.656 0.380 35.9% 0.632 0.368 69.2%
WI siRNA Selection Program Whitehead Institute [78] 9.5 0.019 0.992 53.8% 0.015 0.994 84.6%
DRM RS0.951 18.9 0.021 0.996 72.7% 0.013 0.997 90.9%
DRM RS0.895 20.7 0.032 0.992 66.7% 0.021 0.994 88.9%
DRM RS0.845 38.1 0.032 0.986 54.5% 0.026 0.984 90.9%
DRM RS0.827 51.8 0.037 0.973 42.4% 0.038 0.988 87.9%
Comparison made based on Set T (1,093 siRNA experiments targeting 744 genes). Default settings were used for the 15 online predicting tools. Two sets of parameters (sensitivity, specificity and 
PPV) were calculated for each predicting tool or rule set. One was for > 90% efficacy (that is, a siRNA experiment was considered as truly effective if it achieved > 90% efficacy), the other one was 
for > 70% (considered truly effective if > 70% efficacy was reached in the experiment).BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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when tested with unseen data largely due to the "overfit-
ting" problem in their development [20,24]. Practically,
the key to countering this problem is to make use of a
large siRNA efficacy data from diverse origins when devel-
oping siRNA design rules. In this study, we took advantage
of the recent siRecords collection in our development of
the DRM rule sets. First, we conducted a survey on the
siRecords dataset of all known "features" previously impli-
cated to influence siRNA knock-down efficacy. This survey
resulted in a list of features that significantly boosted the
chance of achieving higher siRNA efficacies. Then, we
examined quantitatively how these significant features
interact with one another in their joint effects on achiev-
ing higher efficacies. The combinations of features that
give rise to the highest levels of boosting to siRNA effica-
cies were picked and reorganized using the DRM algo-
rithm, producing the rule sets. Finally, the performance of
these rule sets was verified on a reserved dataset (Set T,
also from siRecords) and was compared with that of 15
online siRNA design tools commonly used in current
siRNA design practice.
The survey of features influencing RNAi effectiveness con-
ducted in this study is the largest scale survey of this type
ever reported by far (276 features were examined on a
siRNA efficacy dataset consisted of 2,184 records of exper-
iments originated from 1,141 independent studies).
Among the significant features identified in the survey
(Table 1) are several that have been implicated in multiple
previous studies to influence the siRNA efficacy. They
include a few features related to weaker binding on the 3'
end (the 17th nucleotide = A, the 18th nucleotide ≠ C, the
19th nucleotide = (A/U), At least three (A/U)s in the seven
nucleotides at the 3' end, Binding energy of N16–N19 > -9
KCal/Mol, and Binding energy of N16–N19 – binding energy
of N1–N4 is between 0 and 1 KCal/Mol), one feature about
a lower G/C range (G/C content is between 35% and 60%),
two features related to unusual sequence patterns (No
occurrences of four or more identical nucleotides in a row and
No occurrences of G/C stretches of length 7 or longer), one fea-
ture related to melting temperature (Tm is between 20 and
60°C), and one feature related to the target location (Tar-
get site is on CDS). However, there are also a small number
of features that were not reported to be significant in any
previous studies, e.g., the 4th nucleotide = C and the 9th
nucleotide = C. It appears that there are higher levels of dis-
agreements for sequence related features (Categories 1
and 2) than for features defined based on thermodynam-
ics of the siRNAs and on target mRNA sites (Categories 3
and 4) between our survey results and previous findings,
with the exception of the 3-nucleotide segment on the 3'
end (N17–N19, the lower G/C content in this segment is
correlated to lower binding energy on the 3' end). Nota-
bly, three Category 5 features (defined based on experi-
mental settings) Cell line = HeLa, Test method = Western blot
and Test object ≠ mRNA were among those found to be
most significant. Although there have been reports about
siRNA efficacy being influenced by cell lines and test
methods [37-40], this is the first quantitative analysis
about how strong these influences are. More details about
the significant features found in the survey, and compari-
sons of our analyses with previous findings are presented
in the Additional file 1.
In a recently published review article, several considera-
tions for selecting effective siRNAs were proposed result-
ing from summarization and integration of major recent
findings in the field of siRNA design [41]. Comparison of
these considerations with the survey results obtained in
this study indicates that they generally agree with each
The ROC graph shows the performance the DRM rule sets  of several α levels (filled circles) and that of several existing  online predicting tools (open diamonds, "Dharmacon"  denotes Dharmacon Inc.'s siDesign Center, "GenScript"  denotes GenScript Corp.'s siRNA Target Finder, "IDT"  denotes Integrated DNA Technologies Inc.'s RNAi Design  (SciTools), "Invitrogen" denotes Invitrogen Corp.'s BLOCK- iT RNAi Designer, and "siSearch" stands for the siSearch tool  by CGB, Karolinska Institutet) Figure 4
The ROC graph shows the performance the DRM rule sets 
of several α levels (filled circles) and that of several existing 
online predicting tools (open diamonds, "Dharmacon" 
denotes Dharmacon Inc.'s siDesign Center, "GenScript" 
denotes GenScript Corp.'s siRNA Target Finder, "IDT" 
denotes Integrated DNA Technologies Inc.'s RNAi Design 
(SciTools), "Invitrogen" denotes Invitrogen Corp.'s BLOCK-
iT RNAi Designer, and "siSearch" stands for the siSearch tool 
by CGB, Karolinska Institutet). A siRNA experiment was 
considered effective if it achieved > 70% efficacy (was rated 
"high" or "very high" efficacy). The dotted line denotes the 
diagonal of the ROC. Unlike the diagonal line in a ROC of a 
common training task which represents the performance of a 
random guesser, the diagonal line shown in this graph repre-
sents the general siRNA design practice, because this is 
where the siRecords data were obtained. Symbols to the left-
upper side of the diagonal line represent design rules that 
perform better than the general design practice. The farther 
away a symbol is from the dotted line, the better perform-
ance the corresponding design tool presents.
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Table 4: Comparison in performance between 15 online siRNA design tools and 4 DRM rule sets based on independent subset of Set T.
Design Program Institution/Company # Predicted 
effective siRNAs
# Predicted ineffective 
siRNAs
Sensitivity Specificity PPV (%)
Ambion siRNA Target Finder Ambion, Inc. 144 80 0.645 0.362 74.3
Jack Lin's siRNA Sequence Finder Cold Spring Harbor Laboratory 44 180 0.229 0.897 86.4
siDESIGN Center Dharmacon, Inc. 7 217 0.036 0.983 85.7
siRNA Target Finder GenScript Corp. 6 218 0.024 0.966 66.7
Imgenex sirna Designer Imgenex Corp. 24 200 0.114 0.914 79.2
EMBOSS sirna Institute Pasteur 180 44 0.801 0.190 73.8
IDT RNAi Design (SciTools) Integrated DNA Technologies, Inc. 4 220 0.012 0.966 50.0
BLOCK-iT RNAi Designer Invitrogen Corp. 2 222 0.012 1.000 100
siSearch Karolinska Institutet 0 224 N/A N/A N/A
SiMAX MWG-Biotech, Inc. 48 176 0.235 0.845 81.3
BIOPREDsi Novartis Institutes for BioMedical Research 4 220 0.018 0.983 75.0
Promega siRNA Target Designer Promega Corp. 26 198 0.127 0.914 80.8
QIAGEN siRNA Design Tool QIAGEN, Inc. 33 191 0.151 0.862 75.8
SDS/MPI University of Hong Kong 151 73 0.663 0.293 72.8
WI siRNA Selection Program Whitehead Institute 12 212 0.072 1.000 100
DRM RS0.951 1 223 0.006 1 100
DRM RS0.895 4 220 0.024 1 100
DRM RS0.845 5 219 0.030 1 100
DRM RS0.827 9 215 0.048 0.983 88.9
Comparison made based on the independent subset of Set T (224 siRNA experiments targeting 197 genes). Default settings were used for the 15 online predicting tools. A siRNA experiment was 
considered effective if it achieved > 70% efficacy (was rated "high" or "very high" efficacy).BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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other (see Supplementary Table 8 in Additional file 1). Of
the 34 features pertinent to the considerations proposed
by Pei and Tuschl, 29 were found to be significant in
boosting the siRNA efficacy. Among the remaining 5 fea-
tures, the feature G/C content is between 30 and 52% was
found to be associated with a commensurate, though not
significant improvement in the efficacy distribution (P70 =
0.082 and Pwald = 0.056). Two related features, G/C content
is between 35 and 60% and G/C content is between 31.6 and
57.9%, however, were found to be highly significant in
boosting the siRNA efficacy, agreeing with the common
understanding that the effective siRNAs prefer a low-to-
medium G/C content. Two features pertinent to the con-
siderations proposed by Pei and Tuschl that are related to
target accessibility, siRNA passes the repelling loop filter and
Anti-sense siRNA binding energy > -10 KCal/Mol were not
found to be significant in our survey. Yet, two other fea-
tures closely related to them, H-b index < 28.8 and Local
free energy of the most stable structure ≥ -20.9 KCal/Mol, were
found to be significant. The remaining two features perti-
nent to the considerations proposed by Pei and Tuschl,
Binding energy of N6–N11 ≥ -13 KCal/Mol and 10th nucleo-
tide = (A/U), were not found to be significant in our sur-
vey.
Since the siRecords collection is compiled from published
siRNA studies, there is the concern that it may be biased
towards higher efficacy siRNAs, because researchers are
probably less inclined to report lower efficacy experiments
in their research articles. We can assess how much this
bias is by comparing the efficacy distribution of the
siRecords  collection with that of published randomly
designed siRNAs. In two published studies [11,22], mod-
erately large numbers (180) of randomly designed siRNAs
were tested for knock-down efficacies. The percentages of
siRNAs resulting in < 50% efficacies in these two studies
were 22.2% and 23.3%, respectively. In the siRecords data
used in this study, the percentage of records receiving
"low" efficacy rating (i.e., produced < 50% knock-down
efficacies) is 14.3%. In one of these previous studies [22],
the percentage of siRNAs resulting in > 90% efficacies was
reported to be 29.4%. In the siRecords collection, the per-
centage of records receiving "very high" efficacy rating
(i.e., produced > 90% efficacies) is 34.3%. Therefore, the
siRecords collection is indeed biased towards the higher
efficacy experiments, likely because researchers are less
ready to report lower efficacy experiments. However, this
bias is not severe, because nearly 2/3 of the low efficacy
siRNA experiments are still included in siRecords. Further-
more, the analyses conducted in this study – in particular,
the results of the survey of features influencing the siRNA
efficacy – are not influenced by the reduced number of
low efficacy siRNAs in the dataset. These analyses are reli-
able as long as the dataset includes sufficiently large
number of low efficacy records (the number of records
bearing "low" efficacy used in this study is 467).
Another concern over the using of the siRNA data com-
piled from published siRNA studies is that the design of
siRNA experiments in these published studies might be
dominated by one or two design tools used in the per-
formance comparison (Table 3), compromising the objec-
tiveness of this comparison. An analysis of the relative
utility of the 15 online siRNA design tools (see Supple-
mentary Table 7 in Additional file 1) suggested that these
design tools had varied levels of utility, yet none of them
had dominated the current siRNA design practice (see dis-
cussion in Additional file 1).
It is desirable to validate the DRM rule sets obtained in
this study using a dataset independent of siRecords. How-
ever, it is considerably difficult to find a separate siRNA
efficacy dataset that is as large and diverse as the siRecords
collection. In a recent report by Huesken et al., a genome-
wide human siRNA library was constructed, in which
2,431 randomly selected siRNAs targeting 34 fusion
mRNAs were tested for efficacy [42]. There were concerns
when this library of siRNAs was considered as a validation
dataset for the DRM rule sets, because, firstly, this dataset
is of a singular origin; and secondly, fusion mRNAs were
used against which the siRNA efficacies were tested. This
is considered as a somewhat questionable practice
because the native secondary structures may not be well
preserved in the fusion mRNAs. Although Huesken et al.
performed control experiments which suggested that
fusion mRNAs and endogenous mRNAs produced similar
efficacy estimates in the setting they adopted, and argued
that sequence features, rather than secondary structure
related features were the main determinants of the siRNA
efficacy, there have been multiple recent reports about
secondary structures playing important roles in determin-
ing the siRNA efficacy [17,25], which are backed up by the
finding in our survey that at least one secondary structure
related feature (Local folding potential (mean) ≥  -22.72
KCal/Mol) significantly boosts the chance of achieving
higher siRNA efficacy. Nevertheless, we examined the per-
Table 5: Contingency table for the outcome of prediction tasks.
Truly Effective Truly Ineffective
Predicted Effective NA NB
Predicted Ineffective NC NDBMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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formance of the DRM rule sets using the 2,431 siRNA
dataset provided by Huesken et al. The three DRM rule
sets with the highest stringency (RS0.951,  RS0.895  and
RS0.845) identified 23, 32 and 48 effective siRNAs, respec-
tively, in this dataset. These selected siRNAs had average
"normalized inhibitory activity" of 0.80, 0.78 and 0.76,
respectively. When tested using the 249-siRNA test dataset
specified in that study, the same three DRM rule sets iden-
tified 3, 4 and 6 effective siRNAs, respectively, and the
average "normalized inhibitory activity" of these siRNAs
were 0.96, 0.80 and 0.78, respectively. In Huesken et al.,
the average "normalized inhibitory activity" of the entire
dataset was 0.69, and they recommended to use 0.75 or
0.80 as cut-offs for selecting effective siRNAs. These results
suggest that generally speaking, the DRM rule sets were
capable of identifying effective siRNAs in this completely
independent siRNA efficacy dataset.
As more data becomes available in siRecords, we will per-
form updated analyses on this data collection with the
aim of obtaining more accurate and more reliable siRNA
design rules. In addition, as there is indication that the
DRM rule sets behave differently for subpopulations of
siRNAs tested under different experimental settings (e.g.,
for those validated with Western blot technique and those
validated with PCR and other techniques, see Supplemen-
tary Figure 4 in Additional file 1), we will refine our anal-
yses and develop separate rule sets for these different
subpopulations of siRNAs.
Conclusion
In this study, we identified a bundle of highly effective
and generally applicable rule sets for siRNA design. This
was accomplished by applying a simple strategy in which
we analyzed a large number of candidate features for asso-
ciation with increased siRNA efficacies, then used quanti-
tative analyses of the joint effects of these significant
features to identify positive cooperativity among these
features. The key to our approach was the use of the large
set of siRNA efficacy data available in siRecords. The avail-
ability of this dataset not only made the execution of this
strategy possible, but also curbed the overfitting problem
that many rules generated by other design protocols suffer
from. We expect that the design rules revealed in this
study, together with improving RNAi lab techniques, will
make siRNAs a more useful tool for molecular genetics,
functional genomics, and drug discovery studies.
Methods
Data preparation
All records of 19-mer siRNAs (not counting the overhang-
ing nucleotides on the 3' end) were retrieved from the
siRecords database. The records that failed to meet the fol-
lowing criteria were excluded from further analyses: (1)
had complete annotations of cell line types, test methods,
transfection methods and efficacy classification; (2) had
target mRNA lengths ≤ 16,000 nucleotides (this is a limit
set by the Mfold program for calculation of thermody-
namics features, see below); (3) the siRNA sequence had
no mismatches with the targeted site by pair-wise Blast
(NCBI bl2seq v.2.2.9, parameters "-p blastn -W 7 -q -1 -F
F"). For studies where more than 30 siRNA experiments
were reported, we randomly chose 30 to include in our
analyses. The cell line types and test methods were
grouped based on ATCC (American Type Culture Collec-
tion) [43] and Protocol Online [44], respectively.
Features
We define a feature as a binary property of a siRNA exper-
iment concerning a factor potentially influencing the effi-
cacy of the experiment. For a given siRNA experiment, any
defined feature is either present or absent. Some example
features are listed below:
(1) The 6th nucleotide of the siRNA sequence (counting from
the 5' end on the sense strand) is an adenine (A).
(2) The 17th nucleotide of the siRNA sequence is not a guanine
(G).
(3) There are at least three (A/U)'s in the seven nucleotides on
the 3' end.
(4) The G/C content of the siRNA sequence is between 30 and
52%.
For Features (1) and (2), the concerning factors poten-
tially influencing the siRNA efficacy are the identities of
the 6th and the 17th nucleotides of the siRNA sequence,
respectively. For Feature (3), the concerning factor is the
seven nucleotides as a whole on the 3' end of siRNA
sequence. For Feature (4), the concerning factor is the G/
C content of the siRNA sequence.
Each feature has a complementary feature, that is, the alter-
native property concerning the same factor. For instance,
the complementary feature of Feature (1) is the 6th nucleo-
tide of the siRNA sequence ≠ A; and the complementary fea-
ture of Feature (3) is there are at most 2 (A/U)'s in the seven
nucleotides on the 3' end. For any given siRNA experiment
and any given feature, either the feature holds true for the
experiment, or the complementary feature must hold true.
A feature and its complementary feature constitute a fea-
ture pair.
For a given factor, there are multiple ways of formulating
features. In some cases, the so-called sub-feature – super-
feature relationships can result. For example, the following
four features are all concerned with same factor – the iden-
tity of the 6th nucleotide of the siRNA sequence:BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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(5) The 6th nucleotide = A.
(6) The 6th nucleotide ≠ A.
(7) The 6th nucleotide =C.
(8) The 6th nucleotide ≠ C.
Wherever Feature (5) is present, Feature (8) must also be
present. Thus, Feature (5) is a sub-feature of Feature (8),
and Feature (8) is a super-feature of Feature (5). Similarly,
Features (7) and (6) also constitute a pair of sub-feature –
super-feature relationship.
Feature definitions
We surveyed 276 features (constituting 138 feature pairs)
in this study. These features can be classified into the fol-
lowing five categories:
Category 1: Direct sequence features
We defined 152 direct sequence features (76 pairs) based
on the positional specific nucleotide identity in the siRNA
sequence (on the sense strand). For each position in the
19-mer siRNA sequence, 8 features were defined based on
whether or not the nucleotide at the position is an ade-
nine (A), a cytosine (C), a guanine (G), or a uracil (U),
respectively. Among these features, 24 were previously
claimed to favorably influence the siRNA efficacy (see
Supplementary Table 1 in Additional file 1).
Category 2: Sequence-derived features
We defined 38 sequence-derived features (19 pairs) that
are related to either the sequence compositions or the G/
C content of the siRNA (see Supplementary Table 2 in
Additional File 1). All these features have been previously
claimed to have impact on the siRNA efficacy. Among
them, 24 features were defined based on (a) whether or
not the 1st nucleotide is a G/C [13,31,45], (b) whether or
not the 10th nucleotide is an A/U [45], (c) whether the
11th nucleotide is a G/C [14], (d) whether the 19th
nucleotide is an A/U [13,31,45], (e) whether there are at
least 5 (A/U)'s in the last 7 nucleotides at the 3' end [13],
(f) whether there are at least 3 (A/U)'s in the last 7 nucleo-
tides in the 3' end [45], (g) whether there are at least 3 (A/
U)'s in the 5 nucleotides at the 3' end [11], (h) whether
the siRNA contains G/C stretches longer than 9 [13,46],
(i) whether the siRNA contains G/C stretches longer than
7 [18,19], (j) whether there are occurrences of 3 or more
identical nucleotides in a row [18,32], (k) whether there
are occurrences of 4 or more identical nucleotides in a row
[16,18,19,47], and (l) whether there are at least 3 (A/U)'s
in the 5 nucleotides at the 5' end [11], respectively. In
addition, 14 features (7 pairs) were defined based on
whether the G/C content of the siRNA falls into the fol-
lowing reported optimal G/C ranges: (a) 30 – 52% [11],
(b) 32 – 79% [12], (c) 30 – 70% [30], (d) 35 – 60% [18],
(e) 20 – 50% [32], (f) 31.6 – 57.9% [31] and (g) 30 – 79%
[16].
Category 3: Features defined based on thermodynamics of the siRNA
Features on Tm, folding energy of the sense strand and total
hairpin energy. Ten features (5 pairs) were defined that are
related to the melting temperature (Tm) of the siRNA, the
folding energy of sense strand, or the total hairpin energy
of the siRNA. Among them, 6 features were defined based
on whether or not the Tm falls into the following three
ranges < 60°C, < 20°C, and between 20 and 60°C [11].
Two features were defined based on whether or not the
folding energy of sense strand is equal to or greater than -
5 KCal/Mol [18]. Two features were defined based on
whether the absolute value of total hairpin energy is less
than 1 KCal/Mol [24]. The DINAMelt server [48] was used
in the calculation of Tm and hairpin energy [29,49]. The
total hairpin energy was calculated as the absolute value
of the sum of hairpin energies of siRNA sense and anti-
sense strand in units of KCal/Mol [24] (Chalk, A., per-
sonal communication).
Features on binding energy. Sixteen features (8 pairs) related
to the binding energy of siRNA sequences were defined.
On the 5' end binding energy, we defined the feature 5'
binding energy is between -9 and -5 KCal/Mol and its com-
plementary feature [24]. On mid-sequence binding
energy, we defined 6 features associated with three
nucleotide ranges: N6–N11 [22], N7–N11 [15] and N7–
N12 [24]. For the nucleotide range N7–N12, we used the
reported threshold -13KCal/Mol in the feature definition
[24]. For the nucleotide range N7–N11, we defined the
feature based on whether or not the average free energy
profiles fall into the reported optimized range between -
1.97 and -1.65 KCal/Mol [15]. For the binding energy of
the range N6–N11 for which no threshold was explicitly
reported, we took the median value (-13 KCal/Mol) of all
siRNAs in the dataset as the threshold. On 3' end binding
energy, we defined a feature binding energy of N16–N19 >
-9 KCal/Mol and its complementary feature [24]. In addi-
tion, 6 features (3 pairs) were defined that are associated
with the difference between the 5' binding energy and 3'
binding energy. They are defined based on: (a) whether or
not the difference between the binding energy of N1–N4
and N16–N19 is greater than 0 [22,24], (b) whether or not
the difference between the binding energy of N1–N4 and
N16–N19 is between 0 and 1 KCal/Mol [24], and (c)
whether or not the difference between the binding energy
of N1–N5 and N15–N19 is greater than 0 [15], respec-
tively (see Supplementary Table 3 in Additional file 1).
The nearest neighbor model parameters described in Xia,
T. et al. [50] were used for binding energy calculation [29].
The binding energy of N1–N4 and N16–N19 were com-BMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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puted as the sum of free energies for 4 base-pair stacks
starting from position 1 in the sense strand and one single
base stacking energy [21,51] (Chalk, A., personal commu-
nication). Calculations of binding energies for N1–N5
and N15–N19 were performed similarly to those done for
N1–N4 and N16–N19, except that 5 base-pair stacks were
used. Binding energies for N6–N11 and N7–N12 were
computed as the sum of free energies for 6 base-pair stacks
within positions 6–11 and positions 7–12 in the sense
strand. The average free energy profiles of N7–N11 was
computed as the average base pair energy of consecutive
five pentamer subsequences starting from positions 7 to
11 in the sense strand (Poliseno, L., personal communica-
tion).
Category 4: Features defined based on target mRNA sites
Features on the mRNA target location. Sixteen features (8
pairs) related to the siRNA target location on mRNA were
defined, based on whether or not the target region is
within (a) 5' UTR [12,16], (b) 3' UTR [16], (c) CDS[18],
(d) the first 100 nucleotides of CDS [12,16], (e) the first
quartile of CDS, (f) the second quartile of CDS, (g) the
third quartile of CDS[14], and (h) the fourth quartile of
CDS, respectively. The mRNA sequences were obtained
from NCBI GenBank. The target region was determined by
using a BLAST search (NCBI bl2seq v.2.2.9 with parameter
"-W 7 -q -1 -F F"). The targeted site was assigned to a sub-
region if the entire target site lied within that sub-region.
Feature on the secondary structures of the target mRNA. Four-
teen features (7 pairs) that are associated with the second-
ary structures of the target mRNA were defined, based on
(a) whether or not the calculated hydrogene bond (H-b)
index is less than 28.8 [25], (b) whether or not the siRNA
target region is filtered by repelling loop filter [52], (c)
whether or not the local free energy of the most stable struc-
ture (LFE_mss) is equal to or greater than -20.9 KCal/Mol
[53], (d) whether the average local free energy of the ten most
stable structures (LFE_average) is equal to or greater than -
20.85 KCal/Mol [53], (e) whether or not the mean local
folding potential (LFP) is equal to or greater than -22.72
KCal/Mol, (f) whether or not a non-zero accessibility score
was obtained for the siRNA target site [54], (g) whether or
not the anti-sense siRNA binding energy is equal to or less
than -10KCal/Mol [47], respectively (see Supplementary
Table 4 in Additional file 1).
The hydrogen bond (H-b) index measures the average
number of hydrogen bonds formed between nucleotides
in the target region and the rest of mRNA, and it was cal-
culated according to Luo et al. [25]. We used the median
value of all siRNAs in the dataset (28.8) as the threshold
since no threshold was explicitly given in the original
report. The repelling loop filter was proposed by Yiu et al.
for determining the accessibility of the mRNA target
region [52]. If in at least three of the five most stable struc-
tures of the whole-length mRNA (calculated with Mfold),
the 19-mer target site was contained by at least one "big
repelling loop", or by at least two "repelling loops", the
target region was identified to be invalid by the repelling
loop filter. The LFE (local free energy) was calculated
according to Schubert, S., et.al[53], with predicted mRNA
secondary structures calculated using Mfold 3.2 [29,55].
The free energy contribution of each sequence local element
in a structure was extracted from the output .det files by
Mfold; local elements include helices, bulges, and loops
among others. The LFE of the targeted site was computed
as the sum of the free energy contribution of all sequence
local elements containing one or more nucleotides in the
siRNA target site (Schubert, S., personal communication).
The ten most stable secondary structures in the mRNA
sequence were also used in our calculations. For each
siRNA target site, we calculated the LFE for the lowest free
energy structure of the site (LFE_mss) and the average LFE
of the ten most stable secondary structures (LFE_average).
Since no thresholds were explicated provided in the origi-
nal report, the medians of all LFE values in the dataset (-
20.9 KCal/Mol for LFE_mss  and -20.85 for the
LFE_average) were used as thresholds in the feature defini-
tions.
The local folding potential (LFP) is a measurement of the
RNA local thermodynamic stability [56-58]. We postu-
lated that the thermodynamic stability of the siRNA target
site may influence the RNAi effectiveness. We calculated
the structure with the lowest free energy for the 100
nucleotide region on the mRNA centering around each of
the 19 nucleotides in the siRNA target site. The LFP was
calculated as the mean of the 19 free energy values
obtained. In cases when the target site was close to either
end of the mRNA, so that the 100-nucleotide regions
could not be obtained for certain nucleotides in the 19-
mer target site, a shorter mRNA segment was used that was
truncated at the end of mRNA. The median value calcu-
lated for the entire dataset (-22.72 KCal/Mol) was used as
the threshold in feature definition.
The accessibility of the siRNA target region was recently
raised as an important factor influencing the siRNA effi-
cacy [59]. We conducted the Iterative computational analysis
(ICA) using a window size = 800 nucleotides and a step
size = 100 nucleotides [59,60]. To generate the largest
number of windows that overlap the siRNA target region,
the central base of the siRNA target region was used as the
central point of the first window; subsequent windows
were extended in both directions to cover the entire
mRNA sequence. For each window, the five most stable
structures predicted by Mfold were used. It turned out,
however, that the ICA routine produced a filter that is too
stringent for practical use. Of the 2,600 siRNA targetBMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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regions in our dataset, only 6 were determined to be
assessable by this routine. We then took an alternative
approach, and conducted the accessibility score analysis
[54], which produced a similar but less stringent filter. In
calculating the accessibility score, a region receives a non-
zero score as long as the most stable structure in each win-
dow covering the siRNA target region contains a single-
strand segment of length ≥ 10 nucleotides. Of the 2,600
siRNA target regions in our dataset, 456 received non-zero
accessibility scores. Two features were defined based on
this accessibility score filter.
The anti-sense siRNA binding energy was proposed as a
measurement of mRNA accessibility [47]. We used the
Sirna module of the Sfold server to calculate the anti-sense
siRNA binding energy [47]. For each siRNA target sequence,
a 200 nucleotide mRNA segment centering around the 19
nucleotide target site was extracted. In cases when the tar-
get site was close to either end of the mRNA sequence, so
that a 200-nucleotide regions centering around the target
site could not be obtained, a shorter mRNA segment
(truncated at the close end of the mRNA) was used. These
segments were sent to the Sirna server for calculation [61].
The results were parsed and the anti-sense siRNA binding
energies were extracted.
Category 5: Features defined based on experimental conditions
The experimental conditions considered in our analysis
include cell line types, test methods, transfection methods
and test objects. Twelve features (6 pairs) were defined
based on whether or not the RNAi experiment is con-
ducted any of the 6 most frequently used cell lines: (a)
HeLa, (b) HEK293, (c) MCF7, (d) CV-1 and derivatives, (e)
3T3 and (f) T24. Twelve features (6 feature pairs) were
defined based on whether or not the test method is one of
the six most frequently used test methods: (a) Western
blot, (b) PCR (including RT-PCR, real-time PCR etc.), (c)
bDNA, (d) Northern blot, (e) Luciferase assay, and (f)
Flow cytometry. Two features were defined based on
whether the transfection method is synthetic siRNAs or
transcription of hairpin precursors. Four features (2 fea-
ture pairs) were defined based on whether or not the
tested object is (a) mRNA or (b) protein (see Supplemen-
tary Table 5 in Additional file 1).
Statistical tests of features influencing siRNA efficacy
Determined by the four-level scheme used to rate the effi-
cacy of siRNA experiments, proper categorical analysis
techniques were needed to analyze these data. For any
given feature, we calculated the efficacy distribution
(among the four levels – very high, high, medium and
low) of all siRNA experiments carrying this feature, and
compared it with the efficacy distribution of all siRNA
experiments carrying the complementary feature of this
feature. Chi-square (χ2) test of independence is a com-
monly used test that finds evidence of difference between
two discrete distributions. However, this test assumes that
the dependent variable (efficacy rating) is a nominal vari-
able rather than an ordinal variable, thus it is not able to
tell us whether the presence of a feature results in higher
or lower efficacy. A more appropriate test will find evi-
dence of monotone trend, that is, whether the presence of
a feature is associated with a significant up-shift or down-
shift of the efficacy distributions among the four levels.
Consider the joint probability distribution {πi, j} between
the presence/absence of a particular feature (which
defines i: i = 1 if the feature is present, and i = 0 if the fea-
ture is absent), and the four-level efficacy ratings (which
defines j: j = 3 if efficacy rating = "very high", j = 2 if effi-
cacy rating = "high", j = 1 if efficacy rating = "medium",
and j = 0 if efficacy rating = "low"). We calculate the prob-
abilities of concordance and discordance:
Then we calculate the γ  difference between these two
probabilities:
The sample γ has approximately a normal distribution,
with standard error calculated using the Delta method
where
Let
then z2 is a Wald statistics that has a chi-squared null dis-
tribution with 1 degree of freedom, based on which a
Wald test can be conducted to find significant monotone
trend [35].
The monotone trend test finds evidence about whether
the presence of a particular feature is associated with sig-
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nificant up-shift of the four-level efficacy distribution. If
the evidence of such association is found, however, this
test alone is not able to tell us where the up-shift takes
place. In RNAi experiments, we are most concerned with
the chances of achieving higher efficacies. Thus, we also
conducted permutation tests of odds ratios for achieving
> 90% and > 70% efficacies. In the siRecords data, the
chance of achieving > 90% (or > 70%) efficacies can be
approximated by the proportion of records bearing "very
high" (or "high"/"very high") efficacy ratings. For a given
feature, the odds ratio for > 90% efficacies, θ90, is defined
as
where π1, > 90 is the proportion of records bearing "very
high" efficacy rating (i.e., with > 90% efficacies) in the
subset of the experiments carrying the feature, and π0, > 90is
the proportion of records bearing "very high" efficacy rat-
ings in the subset of the experiments carrying the comple-
mentary feature of the feature concerned. To generate a
null distribution of the odds ratio, Set A was randomly
split into two subsets, one of which was arbitrarily marked
with "feature present", the other marked with "comple-
mentary feature present", and an odds ratio was calculated
accordingly. This process was repeated 100000 times, and
the 100000 resampled odds ratios constituted the null
distribution. Given any feature to be tested, the P value
was calculated as
P90 = (i| >  θ90)/100000,
where   is the ith resampled odds ratio, and θ90 is the
true odds ratio of the feature. The odds ratio permutation
test for > 70% efficacies was conducted similarly, with the
proportion of records bearing "very high" or "high" effi-
cacy ratings substituted for that of records bearing "very
high" ratings in the above description.
Meaningful statistics tests require the use of sufficiently
large datasets. All features were subject to a "dataset size
filter" using an arbitrarily set threshold of 30 records: if a
given feature was carried by fewer than 30 records in Set
A, then this feature and the complementary feature of this
feature were excluded from the statistics tests and follow-
ing analyses. Four features – GC stretches of length ≥ 9, G/C
content is not between 30 and 79%, Cell line = T24 and Test
method = Flow cytometry, as well as their complementary
features were excluded for this reason.
Control of false discovery rate (FDR)
The simultaneous testing of the large number of hypothe-
ses requires the curbing of the type I error rate with the
consideration of the "multiple testing" problem. We
chose to control the FDR by taking the q-value approach
[36], because of its ability to adapt to the true distribution
of the input p-values. We used the "bootstrap" method,
rather than the default "smoother" method (which is
equivalent to Benjamini and Hochberg's FDR controlling
method [62]) in estimating the FDR, because U-shape dis-
tributions were observed for the input p-values for both
the Wald test and the odds ratio permutation tests, likely
introduced by the fact that one-sided tests were conducted
when two-sided signals were present [63].
Rules, rule sets and the disjunctive rule merging (DRM) 
algorithm
We define a rule as a conjunction of (l) features. An l-fea-
ture rule is also called an l-feature combination. A rule set
is defined as a disjunction of (m) rules. Generally speak-
ing, the larger m  is, the higher sensitivity the rule set
achieves, in the mean time, the lower specificity the rule
set has to offer.
The disjunctive rule merging (DRM) algorithm was devel-
oped to remove the redundancy in the rule sets resulting
from the combined effect analysis of multiple features, in
the mean time exerting control over the stringency of the
rule sets. The listing of the DRM algorithm is as follows.
Input: Θ: a set of disjunctive rules that contains redun-
dancy; each rule, ri, is a conjunction of mi features: ri = {fi,
f2,...,  }, and is labeled with Pi = the proportion of
records reaching > 90% efficacy in the subset of Set A
records satisfying ri.
α: stringency factor, with a range of [0, 1].
Initialization: Create rule set RS = φ.
Step 1:For every ri ∈ Θ satisfying Pi ≥ α, add ri into RS.
Step 2: For j = 2,3,...,5
For any rule rp ∈ RS where mp = j
For any rule rq ∈ RS where mq > j
if rp ⊂ rq, then remove rq from RS.
End For
End For
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End For
Output: RS: non-redundant set of disjunctive rules with
stringency >α.
It is easy to see that given any α, the rule set resulting from
the DRM algorithm (thus called a DRM rule set) is fixed.
The reverse, however, is not true. A DRM rule set does not
correspond to a single α value, but rather, a range of dif-
ferent  α's. For example, the DRM rule sets for any α
between 0.901 and 1 are exactly the same (containing 7
rules). We note this rule set as RS0.951, where 0.951 is the
mid-point of the range of α for which the rule sets are pro-
duced.
Naturally, the higher α  level, the higher specificity the
DRM rule set possesses; meanwhile, the lower sensitivity
the rule set has to offer. Therefore, the DRM algorithm
with variable α  values allows us to choose the proper
combination of sensitivity and specificity that suits our
needs. In the siRNA design of a typical setting, we are most
concerned with achieving high specificity, and can often
tolerate lower sensitivity, since there is a large pool of pos-
sible target sites to choose from – for a mRNA of length w,
in theory there are (w-19+1) target sites to pick from.
Therefore, we are most concerned with the behavior of the
rule sets with high (close to 1) α values.
Performance comparison between DRM rule sets and 
existing online design tools
Design tasks were performed for the 744 genes in Set T
using the following 15 online siRNA design tools with the
default settings.
Ambion siRNA Target Finder (Ambion, Inc.) [64]. We used
the mRNA sequence as the input. By default, no restriction
of the ending dinucleotides was specified, and no restric-
tion of the G/C content was specified. Occurrences of 4 or
more identical nucleotides in a row were allowed.
Jack Lin's siRNA Sequence Finder (Cold Spring Harbor Labo-
ratory) [65]. We used the full-length mRNA sequence as
the input. The spacer length was set as to be 19.
siDESIGN Center (Dharmacon, Inc.) [66]. We used the
mRNA sequence as the input. No restriction of the leading
sequences was specified. The target region was limited to
the ORF (open reading frame), the G/C content range was
set as 30–52%, and the patterns "GGG" and "CCC" were
excluded. The BLAST filtering option was turned on by
default.
siRNA Target Finder (GenScript Corp.) [67]. We provided
the GenBank accession of the mRNA as the input. The
length of siRNA was set to be 19. By default, the G/C con-
tent range was set to be between 30% and 60%, and
sequence selection region was restricted to the ORF.
Imgenex sirna Designer (Imgenex Corp.) [68]. The target
mRNA was specified using the GenBank accession. The
siRNA length was set to be 19. The parameter "nucleotide
target" was set to be 50 by default. The parameter "first
nucleotide target for siRNA" was set as "AA". The G/C con-
tent range was set to be between 45% and 51%. Occur-
rences of 4 identical A's or T's in a row, or 3 identical (C/
G)'s in a row were not allowed. By default, the BLAST
search was not performed.
EMBOSS siRNA (Institute Pasteur) [69]. We used the full-
length mRNA sequence as the input. By default, no restric-
tion of the leading or ending dinucleotides was specified.
Occurrences of 4 identical nucleotides in a row were
allowed.
IDT RNAi Design (SciTools) (Integrated DNA Technologies,
Inc.) [70]. The mRNA sequence was provided as the input,
and the "21mer" option was selected. The "Unified RNAi
Rule Set" was used in the design. The G/C content range
was set to be between 30% and 70%. The asymmetrical
end stability base pair length was set to be 5. The 5' anti-
sense asymmetrical end stability weight was set to be 0.5,
and the 3' overhang was set to be "TT" by default. The
default setting was also used for all motifs preferences.
BLOCK-iT RNAi Designer (Invitrogen Corp.) [71]. We pro-
vided the mRNA sequence as the input. By default, the
search in the target region was limited to the ORF. The
minimum/maximum allowed G/C contents were set to be
35% and 55%, respectively. The BLAST search option was
turned on by default.
siSearch (Karolinska Institutet) [72]. We provided the
mRNA sequence as the input. By default, the G/C content
range was set to be between 30% and 60%. The candidate
sites with scores of 6 or above were obtained. The mini-
mum energy difference between two ends of the siRNA
was set to be 0. Occurrences of 4 (A/U)'s in a row were not
allowed, and the siRNAs containing immunostimulatory
motifs were removed. The repeat masking was turned on
by default.
SiMAX (MWG-Biotech, Inc.) [73]. We used the Genbank
accession to specify the target. By default, occurrences of >
3 identical nucleotides in a row in the siRNA sequences,
or U's at the 3' end were not allowed. The G/C content
range was set to be between 30% and 53%. The search
range was restricted to the region between the 100th
nucleotide downstream of the start codon and the 100th
nucleotide upstream of the end codon. By default, BLASTBMC Bioinformatics 2006, 7:516 http://www.biomedcentral.com/1471-2105/7/516
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filtering or secondary structure analysis was not per-
formed.
BIOPREDsi (Novartis Institutes for BioMedical Research)
[74]. We used the mRNA sequence as the input. The
number of predicted siRNAs was set to be 10.
Promega siRNA Target Designer (Promega Corp.) [75]. We
used the mRNA sequence as the input. The RNAi system
was set to be the "T7 RiboMAX Express RNAi system". By
default, the target length was set to be 19, and the search
region was set to be the whole input sequence.
QIAGEN siRNA Design Tool (QIAGEN, Inc.) [76]. We spec-
ified the mRNA sequence as the input. The option "Start
siRNA sequence with AA" was turned on by default. The
BLAST search was not performed.
SDS/MPI (University of Hong Kong) [77]. We used the full-
length mRNA sequence as the input. The option "MPI
Principles" was selected. The filtering of ineffective siRNAs
based on secondary structures was not performed. By
default, the G/C content range was set to be between 30%
and 70%, and the search region was restricted to ≥ 100
nucleotides downstream of the CDS.
Whitehead WI siRNA Selection Program (Whitehead Institute
for Biomedical Research) [78]. We used the mRNA sequence
as the input. By default, the sequence pattern "AAN19TT"
was searched for. The G/C content range was set to be
between 30% and 70%. Occurrences of 4 or more identi-
cal T's, A's or G's in a row were not allowed. Occurrences
of 7 or more consecutive (G/C)'s in a row were also not
allowed. By default, the checking with BLAST was not per-
formed.
The performance of a siRNA design rule set, or an online
siRNA design tool, can be assessed by several parameters.
Two of the most often used ones are specificity and sensi-
tivity, as illustrated in Table 5. Specificity is defined as ND/
(NB+ ND); and sensitivity is defined as NA/(NA+ NC). An
ROC (Receiver Operative Characteristic) curve can be
used to visually depict the overall performance of a rule
set. The ROC curve is the plot of sensitivity vs. (1-specifi-
city). Another parameter is the positive predictive value
(PPV), defined as NA/(NA+ NB). The PPV is a very impor-
tant parameter in siRNA design practice, because it
describes out of the siRNAs predicted to be effective, how
big proportion turn out to be truly effective. The value (1-
PPV) is sometimes called the "false positive rate".
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